In Vitro Susceptibility to Quinolones of Francisella tularensis subspecies tularensis

Johansson, Anders; Urich, Sandra K.; Chu, May C.; Sjöstedt, Anders; Tärnvik, Arne

doi:10.1080/00365540110080773

Cited by 52 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The E test strips (AB Biomerieux, Solna, Sweden), including the 13 antibiotics listed in Table 1, were placed on these plates. After incubation at 379 C for 2 days, the minimum inhibitory concentration (MIC) was determined as the MICs of the quality control strains (E. coli and S. aureus) and F. tularensis LVS were similar to the reference MICs found in the instructions of the E test, as reported by Valade et al (9), and MICs reported previously (7,10,15) (Table 1). Using this assay system, ciprofloxacin, doxycycline, erythromycin, and gentamicin effectively inhibited the growth of all isolates with MIC ranges of 0.003-0.023, 0.094-1.5, 0.094-1.5, and 0.023-0.5 mg/L, respectively (Table 2).…”

mentioning

confidence: 82%

In Vitro Antibiotic Susceptibility of <i>Francisella tularensis</i> Isolates from Japan

et al. 2013

View full text Add to dashboard Cite

SUMMARY:The antibiotic susceptibilities of 36 isolates of Japanese Francisella tularensis, an etiological agent of the zoonotic disease tularemia, were analyzed using the E test. All the isolates were susceptible to ciprofloxacin, doxycycline, erythromycin, and gentamicin but resistant to benzylpenicillin and cephalothin. The susceptibility to seven other b-lactams (aztreonam, cefotaxime, cefoxitin, ceftriaxone, cefuroxime, imipenem, and meropenem) varied among the isolates. These findings suggest that the guidelines for the antibiotic treatment of tularemia issued by the World Health Organization are appropriate for Japanese tularemia patients.

show abstract

mentioning

confidence: 82%

In Vitro Antibiotic Susceptibility of <i>Francisella tularensis</i> Isolates from Japan

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Bu dozda doksisiklin kullanılmasıyla serumda ortalama 4 mg/lt ilaç konsantrasyonuna ulaşılmaktadır (33). Doksisiklinin F. tularensis için minimum inhibitör konsantrasyonu (MİK)'nun 0.25-2 mg/lt arasında olmasına dayanarak serumdaki bu ilaç konsantrasyonu optimum antibakteriyel aktivite için yeterli görülmektedir (24)(25)(26)(27)34,35).…”

Section: Tetrasiklinlerunclassified

“…Kinolonların alt tür tularensis kökenlerine karşı MİK değerleri alt tür holarctica izolatlarına benzer olarak bulunmuştur (34,35). Ancak, kinolonların (siprofloksasinin) alt tür tularensis infeksiyonunun tedavisindeki etkinliğine dair çok az veri bulunmaktadır.…”

Section: Kinolonlarunclassified

“…Ülkemizdeki çalışmalarda, tüm izolatlar eritromisin, azitromisin, trimetoprim-sülfametoksazol, klindamisin ve imipeneme dirençli olarak bulunmuştur (50). Rifampisin in vitro etkili bulunmasına rağmen, direnç gelişimi potansiyeli nedeniyle kullanımı önerilmemektedir (24)(25)(26)35). Bugüne kadar imipenem ile başarılı bir şekilde tedavi edilen tek olgu bildirilmiştir (17).…”

Section: Diğer Antibiyotiklerunclassified

“…tularensis suşlarında aminoglikozid, tetrasiklin, kloramfenikol ve kinolonlara karşı doğal direnç bildirilmemiştir. Ancak, eritromisine karşı doğal direnç Kuzey Avrupa'da (özellikle İskandinavya), Rusya'nın endemik bölgelerinde ve ülkemizde yaygındır (24)(25)(26)35,49). Eritromisin direnci epidemiyolojik bir gösterge olarak kullanılabilir (2,7).…”

Section: F Tularensis'in Antibiyotik Direnciunclassified

See 2 more Smart Citations

Tularemia: A General Overview on Current Treatment Options

Kılıç¹,

Yeşilyurt²

2011

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTularemi, Francisella tularensis'in etken olduğu, dünya çapında bir dağılım gösteren ve farklı klinik belirtilerle seyreden zoonotik bir infeksiyon hastalığıdır. İnsanlarda klinik tablo lokalize hastalıktan fülminan, yaşamı tehdit eden pnömoni veya septisemiye kadar değişmektedir. Tularemi tedavisinde yıllardır streptomisin, gentamisin ve tetrasiklin kullanılmaktadır, ancak son zamanlarda kinolonlar önemli bir alternatif olarak kabul edilmektedir. AbstractTularemia is a zoonotic infection caused by Francisella tularensis with a worldwide distribution and diverse clinical manifestations. In humans, the disease varies from a localized illness to fulminant, life-threatening pneumonia or septicemia. For decades, streptomycin, gentamicin, and tetracycline have been used for the treatment of tularemia, but more recently, quinolones have been considered as acceptable alternatives. However, there are no randomized trials supporting the use of these antibiotics compared with each other. The increasing number of tularemia outbreaks in regions of Turkey outside the classic endemic areas in recent years has prompted renewed interest in this infectious disease. In this review, suggestions about treatment of tularemia are presented in the light of current literature. Klimik Dergisi 2011; 24(1): 2-10.

show abstract

Tularemia (Francisellatularensis)

Johansson¹

2005

Encyclopedia of Bioterrorism Defense

View full text Add to dashboard Cite

Tularemia is a zoonosis, a disease of animals transmissible to humans, and is caused by the facultative intracellular bacterium Francisella tularensis. F. tularensis is considered a potential agent of biological warfare and bioterrorism and as such has been rated among the top 6 category A agents. Formerly, F. tularensis was included among agents developed and used by state‐sponsored bioweapons programs. In fact, F. tularensis is one of the most infectious pathogenic bacteria known, requiring inoculation or inhalation of as few as 10 organisms to cause human infection. At present there are four recognized subspecies of F. tularensis: tularensis, holarctica, mediasiatica, and novicida. The natural reservoirs of F. tularensis still await complete delineation. Little is known about the virulence mechanisms of F. tularensis. In a bioterrorism scenario, respiratory tularemia (acquired through inhalation) is judged to be the greatest threat. Natural outbreaks of human respiratory type A or type B tularemia have repeatedly been recorded in farmers and landscape workers illustrating the potential of effective F. tularensis transmission by dry aerosols. The clinical expression of tularemia largely depends on the route of entrance of the infectious agent and the prognosis in tularemia is highly dependent on the causative subspecies of F. tularensis. There is currently no licensed and widely available tularemia vaccine. Tularemia warrants antibiotic treatment and is not transmitted from person to person. Currently, there is a reawakened interest in tularemia and a rapid development of new diagnostics, prophylactics and therapies.

show abstract

In Vitro Susceptibility to Quinolones of Francisella tularensis subspecies tularensis

Cited by 52 publications

References 12 publications

In Vitro Antibiotic Susceptibility of <i>Francisella tularensis</i> Isolates from Japan

In Vitro Antibiotic Susceptibility of <i>Francisella tularensis</i> Isolates from Japan

Tularemia: A General Overview on Current Treatment Options

Tularemia (Francisellatularensis)

Contact Info

Product

Resources

About